search
Back to results

Pilot Trial of ExACT (Exercise as Airway Clearance Therapy) for People With Cystic Fibrosis (ExACT-CF)

Primary Purpose

Cystic Fibrosis

Status
Active
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Exercise as Airway Clearance Therapy (ExACT)
Sponsored by
University Hospital Southampton NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cystic Fibrosis

Eligibility Criteria

10 Years - 60 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • CF diagnosis based on sweat chloride >60mmol/L and CFTR genotype which includes at least one phe508del allele
  • Clinically stable
  • Baseline lung function (as measured by FEV1) of >40% predicted
  • ≥ 10 years of age
  • Established (>3 months) on Elexacaftor in combination with Tezacaftor and Ivacaftor (ETI) - Kaftrio®.
  • Under the care of the paediatric centres in Southampton and Edinburgh and/or adult centres in Southampton, Edinburgh*

    *Paediatric and Adult sites in Glasgow may be utilised in event of under-recruitment to the study

  • Able to cooperate with the study protocol

Exclusion Criteria:

  • Considered clinically unstable by recruiting physician e.g. frequent exacerbations (>3/year in preceding 2 years), variable lung function (FEV1<40% predicted and/or excursions of >20% from baseline). Patients will not be excluded due to any pathogen as long as they are deemed clinically stable.
  • Health contraindications to exercise e.g. arthritis, cardiac disease
  • Not willing to give consent or to take part in the study (N.B. children will provide assent and require parent/guardian consent)
  • Insufficient understanding in regard the trial - e.g. not capable of giving informed consent.
  • Previously randomised into this trial
  • Participation in a concurrent intervention study in the past 2 months

Sites / Locations

  • Dr Zoe Saynor

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Usual Care

Exercise as Airway Clearance Therapy (ExACT)

Arm Description

In line with current guidelines [4], participants will continue chest physiotherapy as advised by their physiotherapist (at least one session of ACT/day) and continue to undertake exercise and physical activity at their usual levels.

Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET) - agreed in our e-Delphi exercise REF and wider PPI discussion as possible alternatives for airway clearance. This intervention we term ExACT*. The undertaking of ExACT at least once per day is expected of those randomised to Arm 2. *Although routine chest physiotherapy is being replaced by ExACT, chest physiotherapy is permissible in the event of a chest exacerbation and a protocol deviation will be recorded.

Outcomes

Primary Outcome Measures

Number of participants recruited into study (quantitative)
Number recruited and randomised 1:1 into the study

Secondary Outcome Measures

Number of participants completing study (quantitative)
The proportion of people with CF that attend their baseline visit who also attend the Day 28 visit
Number of people completing study
Proportion of people with CF who complete the study and submit and necessary data
Number of people who choose intervention
The proportion of people with CF that would chose the intervention over usual care (chest physiotherapy) in the future
Qualitative interview data
Thematic analysis of semi-structured interviews of participants and healthcare professional involved with the study
Change in LCI2.5
Between group differences in change in LCI2.5 from baseline to Day 28 after intervention
Change in Forced Expiratory Volume in the 1st second (FEV1) (%predicted)
Between group differences in change in FEV1 (%predicted) from baseline to Day 7, 14, 21 and Day 28
Change in Forced Vital Capacity (FVC) (%predicted)
Between group differences in change in FEV1 (%predicted) from baseline to Day 7, 14, 21 and Day 28
Rates of pulmonary exacerbations
Between group differences in rates of pulmonary exacerbation from baseline to Day 28
Number of adverse events
Between group differences in adverse events and serious adverse event rates from baseline to Day 28
Device-based physical activity (Garmin Vivosmart4 watch)
Between group differences in the amount/type/intensity of physical activity and exercise from baseline to Day 28
Mood
Between group differences in change in mood (HADS) and any change from baseline to Day 28
Quality of life (CFQ-R)
Between group differences in quality of life and any change from baseline to Day 28
Treatment burden
Between group differences in change in treatment burden (CFQ-R Treatment Burden subscale) and any change from baseline to Day 28
Habitual activity estimation scale (HAES)
Between group differences in change in HAES and any change from baseline to Day 28
EQ-5D-5L
Between group differences in change in EQ-5D-5L and any change from baseline to Day 28
Sleep
Between group differences in total sleep time and any change from baseline to Day 28

Full Information

First Posted
July 21, 2022
Last Updated
September 26, 2023
Sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
Royal Hospital for Children and Young People, Edinburgh, University of Edinburgh, Cystic Fibrosis Trust, Department of Sport, Exercise and Rehabilitation, University of Northumbria at Newcastle, Department of Psychology, University of Portsmouth, Queen Elizabeth University Hospital Glasgow, Newcastle-upon-Tyne Hospitals NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT05482048
Brief Title
Pilot Trial of ExACT (Exercise as Airway Clearance Therapy) for People With Cystic Fibrosis
Acronym
ExACT-CF
Official Title
ExACT-CF: Exercise as an Airway Clearance Technique in People With Cystic Fibrosis - A Randomised Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 2, 2023 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
Royal Hospital for Children and Young People, Edinburgh, University of Edinburgh, Cystic Fibrosis Trust, Department of Sport, Exercise and Rehabilitation, University of Northumbria at Newcastle, Department of Psychology, University of Portsmouth, Queen Elizabeth University Hospital Glasgow, Newcastle-upon-Tyne Hospitals NHS Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Cystic fibrosis (CF) is the UK s most common inherited genetic condition and affects more than 10,500 people. The disease causes problems with the movement of salt and water in the body, resulting in sticky mucus building up, mostly in the lungs and gut. Thick mucus in the airways leads to repeated infections which, over time, damage the lungs. Chest physiotherapy is prescribed to loosen and clear sticky thick mucus from the airways and so to help to reduce lung infection. Chest physiotherapy is a routine treatment to keep people with CF healthy. However, many say it is time-consuming and a burden. People with CF have asked if doing exercise could have the same effect as chest physiotherapy sessions for helping clear mucus. Exercise could be more enjoyable and less burdensome. Through a recognised priority setting partnership, the CF community recently ranked research to reduce the burden of their care and answer whether exercise can replace chest physiotherapy , as their number 1 and 7 priorities. Surveys show that many people with CF have occasionally chosen to replace chest physiotherapy with exercise for airway clearance, and we recently confirmed this through a UK-wide survey. It is not known if they would be willing to take part in research that asks some to stop chest physiotherapy and to exercise (with coughs and huffs) instead. New medicine (modulators) have recently become available for many people with CF, bringing dramatic improvements in their health. Some people who have started modulators are considering whether they can reduce or stop treatments - including chest physiotherapy. So, the effects of stopping chest physiotherapy need to be investigated and also if exercise can be used instead - this research study aims to understand this. A recent survey in people with CF, their families, physiotherapists and doctors, conducted by this research team, showed us that many consider hard exercise with coughs and huffs to be able to clear mucus from the airways. This study will recruit 50 people with CF (>12 years old) for 28-days. This study will ask half of them to continue their usual care, and half to stop chest physiotherapy and do exercise that gets them breathing deeply (with coughs and huffs) instead. This study will see if people are willing to start and continue with such a study and what they think of the study processes. It will also see how stopping chest physiotherapy and replacing it with exercise affects measurements of their lung function. The study will also involve talking with people with CF and members of their CF team to understand their experiences. This information will reveal whether a larger study can answer the question of whether certain forms of exercise can safely be used as an alternative to chest physiotherapy.
Detailed Description
Cystic fibrosis (CF) is the UK's most common inherited genetic condition and affects more than 10,500 people. People with CF have problems with the movement of salt and water in the body, which causes sticky mucus to build up, mostly in the lungs and gut. Thick mucus in the airways leads to repeated infections which may, over time, damage the lungs. All people with CF are therefore asked to use chest physiotherapy 1-2 times a day, to loosen and clear sticky thick mucus from their airways and help reduce their risk of getting a lung infection. Chest physiotherapy is viewed as a routine treatment to keep people with CF healthy. However, many say it is time-consuming and a burden. People with CF have asked if doing exercise could have the same effect as chest physiotherapy sessions for helping clear mucus. Exercise could be more enjoyable and less burdensome and people with CF are already asked to do it regularly to stay fit and well. Surveys show that many people with CF occasionally choose to replace chest physiotherapy with exercise for airway clearance - we recently confirmed this in a UK-wide survey. It is unknown whether people with CF would be willing to take part in research that asks them to either continue with chest physiotherapy, or to stop this and do exercise (with coughs and huffs) instead. New medicines (CFTR modulator drugs) have recently become available for many people with CF, bringing dramatic improvements in their health. Many people who have started modulators are considering whether they can reduce or stop other treatments, including chest physiotherapy. So, the effects of stopping chest physiotherapy need to be studied and research is needed to find out if exercise can be used instead - this research study aims to understand this. A recent survey in people with CF, their families, physiotherapists and doctors, undertaken by this research group, revealed that most people with CF consider exercise with coughs and huffs to be able to clear mucus from the airways in a similar manner to chest physiotherapy. This study will recruit 50 people with CF who are older than 10 years of age for 28-days. It will randomly ask half of them to continue their usual care (chest physiotherapy), and half to stop chest physiotherapy and use exercise airway clearance therapy at least once a day instead - which will be explained to them. Briefly this will involve exercise that is ~20 minutes in duration, at a level where they must breathe deeply, used types of exercise from a list we will provide, and include assessment breaths, coughs and check huffs to help clear any sticky mucus. This study will see if people are willing to start and continue with such a study and what they think of the study processes. It will also see how stopping chest physiotherapy and replacing it with regular exercise affects the lungs. It will also involve talking with people with CF and members of their CF team to understand their experiences of the research study. This information will reveal whether a larger study can answer the question of whether certain forms of exercise can safely be used as an alternative to chest physiotherapy and also improve what we are doing in any areas if needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Two-arm randomised, pilot trial with an embedded qualitative component
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
In line with current guidelines [4], participants will continue chest physiotherapy as advised by their physiotherapist (at least one session of ACT/day) and continue to undertake exercise and physical activity at their usual levels.
Arm Title
Exercise as Airway Clearance Therapy (ExACT)
Arm Type
Experimental
Arm Description
Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET) - agreed in our e-Delphi exercise REF and wider PPI discussion as possible alternatives for airway clearance. This intervention we term ExACT*. The undertaking of ExACT at least once per day is expected of those randomised to Arm 2. *Although routine chest physiotherapy is being replaced by ExACT, chest physiotherapy is permissible in the event of a chest exacerbation and a protocol deviation will be recorded.
Intervention Type
Other
Intervention Name(s)
Exercise as Airway Clearance Therapy (ExACT)
Intervention Description
Arm-2 (ExACT): Participants will be advised to replace routine chest physiotherapy sessions with exercise combined with coughs and huffs - also referred to as forced expiratory techniques (FET). The undertaking of ExACT at least once per day is expected. Written and verbal instruction will be provided on the type, duration, frequency and intensity of exercise that is considered adequate replacement for routine chest physiotherapy. A compendium of allowable activity types, and the required times at different intensities that are considered to replace chest physiotherapy for ACT The research team will support exercise advice in line with standard care if subjects request this. The trial has no other changes to CF care. All medications, nutritional support and other treatments continue.
Primary Outcome Measure Information:
Title
Number of participants recruited into study (quantitative)
Description
Number recruited and randomised 1:1 into the study
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Number of participants completing study (quantitative)
Description
The proportion of people with CF that attend their baseline visit who also attend the Day 28 visit
Time Frame
28 days
Title
Number of people completing study
Description
Proportion of people with CF who complete the study and submit and necessary data
Time Frame
6 months
Title
Number of people who choose intervention
Description
The proportion of people with CF that would chose the intervention over usual care (chest physiotherapy) in the future
Time Frame
6 months
Title
Qualitative interview data
Description
Thematic analysis of semi-structured interviews of participants and healthcare professional involved with the study
Time Frame
6 months
Title
Change in LCI2.5
Description
Between group differences in change in LCI2.5 from baseline to Day 28 after intervention
Time Frame
28 days
Title
Change in Forced Expiratory Volume in the 1st second (FEV1) (%predicted)
Description
Between group differences in change in FEV1 (%predicted) from baseline to Day 7, 14, 21 and Day 28
Time Frame
28 days
Title
Change in Forced Vital Capacity (FVC) (%predicted)
Description
Between group differences in change in FEV1 (%predicted) from baseline to Day 7, 14, 21 and Day 28
Time Frame
28 days
Title
Rates of pulmonary exacerbations
Description
Between group differences in rates of pulmonary exacerbation from baseline to Day 28
Time Frame
28 days
Title
Number of adverse events
Description
Between group differences in adverse events and serious adverse event rates from baseline to Day 28
Time Frame
28 days
Title
Device-based physical activity (Garmin Vivosmart4 watch)
Description
Between group differences in the amount/type/intensity of physical activity and exercise from baseline to Day 28
Time Frame
28 days
Title
Mood
Description
Between group differences in change in mood (HADS) and any change from baseline to Day 28
Time Frame
28 days
Title
Quality of life (CFQ-R)
Description
Between group differences in quality of life and any change from baseline to Day 28
Time Frame
28 days
Title
Treatment burden
Description
Between group differences in change in treatment burden (CFQ-R Treatment Burden subscale) and any change from baseline to Day 28
Time Frame
28 days
Title
Habitual activity estimation scale (HAES)
Description
Between group differences in change in HAES and any change from baseline to Day 28
Time Frame
28 days
Title
EQ-5D-5L
Description
Between group differences in change in EQ-5D-5L and any change from baseline to Day 28
Time Frame
28 days
Title
Sleep
Description
Between group differences in total sleep time and any change from baseline to Day 28
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: CF diagnosis based on sweat chloride >60mmol/L and CFTR genotype which includes at least one phe508del allele Clinically stable Baseline lung function (as measured by FEV1) of >40% predicted ≥ 10 years of age Established (>3 months) on Elexacaftor in combination with Tezacaftor and Ivacaftor (ETI) - Kaftrio®. Under the care of the paediatric centres in Southampton and Edinburgh and/or adult centres in Southampton, Edinburgh* *Paediatric and Adult sites in Glasgow may be utilised in event of under-recruitment to the study Able to cooperate with the study protocol Exclusion Criteria: Considered clinically unstable by recruiting physician e.g. frequent exacerbations (>3/year in preceding 2 years), variable lung function (FEV1<40% predicted and/or excursions of >20% from baseline). Patients will not be excluded due to any pathogen as long as they are deemed clinically stable. Health contraindications to exercise e.g. arthritis, cardiac disease Not willing to give consent or to take part in the study (N.B. children will provide assent and require parent/guardian consent) Insufficient understanding in regard the trial - e.g. not capable of giving informed consent. Previously randomised into this trial Participation in a concurrent intervention study in the past 2 months
Facility Information:
Facility Name
Dr Zoe Saynor
City
Portsmouth
State/Province
Hampshire
ZIP/Postal Code
PO1 2ER
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pilot Trial of ExACT (Exercise as Airway Clearance Therapy) for People With Cystic Fibrosis

We'll reach out to this number within 24 hrs